Xenon Pharmaceuticals (XENE) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts XENE Hot Sheet
Join SI Premium – FREE
Xenon Pharmaceuticals (NASDAQ: XENE) reported Q3 EPS of ($0.81), $0.01 better than the analyst estimate of ($0.82). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .
For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Graco Inc. (GGG) PT Lowered to $80 at DA Davidson
- SS&C Technologies shares fall on weak Q4 revenue outlook
- Dollar Tree shares drop amid analyst downgrade pressure
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
